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creativecommons.org/licenses/by-nc-nd/Abstract Purpose: Real-World Data (RWD) studies are increasingly used to support regula-
tory approvals, reimbursement decisions, and changes in clinical practice for novel cancer
drugs. However, few studies have systematically appraised their quality or compared out-
comes to pivotal trials.
Methods: All RWD studies (2010e2019) for drugs approved by the Food and Drug Admin-
istration (FDA) and European Medicines Agency (EMA) from 2010 to 2015 for solid organ
tumours in the non-curative setting were identified. Quality assessment was undertaken using
the Newcastle Ottawa Scale. Survival differences between each RWD study and the pivotal
trial were determined using a related sample Wilcoxon signed-rank test.
Results: 293 RWD studies for 45 of the 57 drug indications approved by the FDA/EMA were
identified. The most common tumour types were prostate cancer (29%, nZ 86) and melanoma
(15%, n Z 43). A quarter of the studies had industry funding. No high-quality studies were
identified, and 78% were low quality. Comparative survival analysis between RWD andf Health Services Research and Policy, Tavistock Place, London, WC1H 9SH, United Kingdom.
.ac.uk (A. Aggarwal).
2 AA and CB are joint final authors.
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J.M. Boyle et al. / European Journal of Cancer 155 (2021) 136e144 137pivotal trials was possible for 224 studies (37 drug indications). Differences in median survival
between the RWD studies and their corresponding trial ranged from 32 months to 21
months (IQR e4$2 months to 1$6 months). Low-quality studies were more likely to report
superior survival outcomes (23%) compared to higher quality studies (8%) (p Z 0.02).
Conclusion: RWD study quality for novel cancer drugs is low and of insufficient rigour to
inform reimbursement decisions and clinical practice. RWD studies seeking publication
should provide a completed quality assessment tool on submission. Greater investment in
properly designed RWD studies is required.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Real-World Data (RWD) is population- or institution-
level data collected either prospectively or
retrospectively from non-randomised observational
sources such as electronic health records [1], billing
claims, insurer databases, and disease registries [2,3].
RWD has rapidly expanded to influence and inform a
wide range of activities from regulatory
approvals through to health technology assessment
(HTA) and clinical guidelines [4].
RWD studies allow an assessment of treatment
effectiveness in diverse non-selected populations and are
an important adjunct to Randomised Controlled Trials
(RCTs), particularly to obtain data on late toxicities,
rare events, and long-term outcomes [1,5,6]. They also
offer critical insights into the quality and outcomes
achieved in routine practice, particularly for the vast
majority of patients who would not meet eligibility
criteria for RCTs. In contrast, RCTs have been
considered the gold standard for measuring the efficacy
and short-term toxicity of an intervention. The simple
act of randomisation ensures high internal validity (ie
ability to capture ‘true’ treatment effect); however, strict
eligibility criteria can limit the external validity (ie gen-
eralisability) of results [7].
Regulatory agencies such as the Food and Drug
Administration (FDA) have demonstrated an increased
willingness to use RWD data to support marketing
authorisations [4]. HTAs are also increasingly
requesting RWD to assess whether interventions pro-
vide clinically meaningful benefits, particularly in light
of the lowering of thresholds for regulatory approval
by both the FDA and European Medicines Agency
(EMA) [8,9]. In circumstances where uncertainties exist
in the post-marketing setting, RWD is being used to
define conditional reimbursement schemes or managed
entry agreements. For example, coverage with evidence
development (CED), risk-sharing agreements, or pay-
ments for outcomes [10].
However, several potential flaws with the use of
RWD for these processes have been highlighted,
particularly around the use of historical controls and
surrogate endpoints, as well as issues regarding data
quality and its validity [4,11].The role of RWD to support drug regulatory de-
cisions, HTA, and clinical practice guidelines, therefore,
continues to be the subject of ongoing consultation and
debate [12,13]. However, these discussions are being
undertaken in the absence of a systematic assessment of
RWD to understand the quality of the studies presently
undertaken and the outcomes typically delivered in
‘real-world’ populations.
In this study, we sought to empirically evaluate all
contemporary RWD studies reporting the effectiveness
of cancer drugs for the treatment of advanced/metastatic
solid organ malignancies published over the last 10
years. Our specific objectives were to describe their
quality and the extent to which survival outcomes for
patients in the real world were comparable to those
observed in their pivotal RCTs.
2. Methods
This retrospective cohort study included all published
RWD studies reporting the effectiveness of new cancer
therapies that had been approved by the FDA and EMA
between 1st January 2010 and 31st December 2015. We
limited the cohort analysis to all antineoplastic and
immunomodulating agents for solid tumours used in the
non-curative setting (which accounts for approximately
97% of all indications). For all drug indications, we
identified the corresponding pivotal trial through a re-
view of the EMA and FDA approval documents (RCT
or Phase 2 trial).
To identify relevant observational studies, we
searched PubMed for each approved drug indication.
Our search strategy included the drug name, approved
indication, and search terms for ascertaining real-world
studies (‘real world’, ‘population based’, ‘cohort’,
‘observational’, ‘registry’, ‘access scheme’). This was
repeated for each drug indication and the list of relevant
studies to enable comparison. Our latest search was on
31st July 2019, which allowed at least 4$5 years for the
completion and publication of RWD studies.
Fully published reports were eligible if they reported
survival outcomes in the same indication, combination,
and line of therapy as the FDA/EMA approval.
Observational studies with mixed populations ie, had a
proportion of patients receiving the drug in an earlier
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backbone (other standard chemotherapy agents given
with the drug of choice) were also included. Studies were
excluded if the drug was used solely in an earlier line of
therapy compared to the pivotal trial, a different
chemotherapy backbone was used, and/or the study did
not seek to assess the survival of patients in the study
cohort.
Of the studies meeting the inclusion criteria, survival
analysis was restricted to those RWD studies for which
both the RWD study and pivotal trial reported the
median overall survival. RWD studies reporting the
median survival for only a subset of the whole study
population, different treatment backbone, or for an
earlier line of therapy were excluded.
Data extracted included: location of study, study type
(multicentre/single centre), number of patients receiving
an intervention, prospective or retrospective evaluation,
line of therapy, and chemotherapy backbone used,
where applicable. The age, gender, and performance
status of participants were included, as well as the me-
dian overall survival observed where available. The
source of study funding and whether the article was
open access was also recorded.
2.1. Quality assessment
To assess the quality of the included studies, we used the
Newcastle Ottawa Scale (NOS) that scores cohort
studies 0e9 according to eight criteria across three do-
mains: (1) selection of the study groups; (2) compara-
bility of groups; and (3) ascertainment of exposure and
outcome. However, most studies identified in our cohort
were single-centre case series evaluating the intervention
alone or sought to compare the intervention drug with
another comparator drug not used in the pivotal study.
To evaluate the intervention arm, we used the previously
validated modified Newcastle Ottawa scoring system for
the case series, which scores the intervention arm on a
scale of 0e6 [14]. This scoring system is derived from the
original NOS but excludes an assessment of the
comparability of the intervention and non-intervention
arm. In line with the previous use of the NOS [15]
appraisal tool, studies with scores of 0e3 have a high
risk of bias and are considered of low quality. Studies
with scores of 4e6 are of moderate quality, and studies
with scores of 7e9 are at low risk of bias and considered
of high quality. Quality assessment was performed
independently by GH, JB, EHJ, and JD. AA performed
a random duplicate assessment of 20% of the papers.
2.2. Survival analysis
For each drug-approved indication, we collated RWD
studies meeting our inclusion criteria for the survival
analysis and plotted the difference in median overall
survival between each observational study and theircorresponding pivotal trial. A frequency table was
then produced to demonstrate the proportion of
observational studies across all drug indications for
which the median overall survival outcomes were
greater or less than the index study. A Related Sample
Wilcoxon signed-rank test was performed to assess
whether the overall difference across all studies was
statistically significant. We also assessed the propor-
tion of RWD studies that reported median overall
survival, which was better, comparable or worse than
the index study using both a 10% and then a 20%
survival threshold.3. Results
From 2010 to 2015, the EMA and FDA approved the
use of 50 drugs for 57 solid organ cancer indications in
the advanced or metastatic setting (Supplementary
Table 1). These approvals were supported by 60 clin-
ical trials, 55 of which were phase III RCTs. Of 4672
RWD studies identified by the search strategies, 323 full-
text articles were deemed potentially eligible and
reviewed in full. We subsequently excluded 30 studies
(Supplementary Fig. 1) because they did not assess
overall survival; a composite survival was reported
across different drug combinations; or the study was a
duplicate, which presented data from a cohort of pa-
tients already included as part of another study. The
final study cohort included 293 RWD studies for 45 of
the 57 indications.3.1. Characteristics of RWD studies
Characteristics of all RWD (n Z 293) studies identified
are shown in Table 1; 98% (n Z 288) of RWD studies
were case series. Five studies were comparative cohort
studies, which replicated the comparison undertaken in
the pivotal trial. The most common tumour types were
prostate (29%, n Z 86), melanoma (15%, n Z 43),
colorectal (12%, n Z 34), lung (11%, n Z 33), and renal
(11%, n Z 32). The mechanism of action of agents in the
studies of RWD were small molecule inhibitors (37%,
n Z 108), cytotoxic agents (22%, n Z 65), hormonal
agents (17%, n Z 50), and monoclonal antibodies (16%,
n Z 48).
Three-quarters of studies (76%, n Z 223) originated
from eleven countries across Europe (Italy, France,
Spain, UK, the Netherlands, and Poland), South East
Asia (Japan, China, and South Korea), and North
America (the USA and Canada). Of these countries,
Italy published the largest number of studies (18%,
n Z 52) followed by Japan (10%, n Z 30), and China
(10%, n Z 28) (Table 1).
Only 2% of studies (n Z 6) used data from national
cancer registries, and 38% (n Z 112) were from single-
Table 1
Characteristics of the RWD studies (n Z 293 for 45 drug indications)
identified for FDA and EMA approved indications, including RWD









No. % No. %
Indication
Prostate 86 29.4 72 32.1
Melanoma 43 14.7 33 14.7
Colorectal 34 11.6 34 15.2
Lung 33 11.3 16 7.1
Renal 32 10.9 24 10.7
Breast 23 7.8 16 7.1
Gastric 16 5.5 14 6.3
Sarcoma 13 4.4 7 3.1
Thyroid 7 2.4 4 1.8
Pancreatic 3 1.0 3 1.3
Ovarian 3 1.0 1 0.4
Drug Type
Small molecule inhibitor 108 36.9 73 32.6
Cytotoxic 65 22.2 57 25.4
Hormonal 50 17.1 40 17.9
Monoclonal antibody 48 16.4 40 17.9
Radionucleide 14 4.8 11 4.9
Immunotherapy 7 2.4 3 1.3
Vaccine 1 0.3 0 0.0
Country
Italy 52 17.7 44 19.6
Japan 30 10.2 22 9.8
China 28 9.6 22 9.8
USA 26 8.9 16 7.1
France 22 7.5 18 8.0
Spain 15 5.1 12 5.4
Canada 14 4.8 9 4.0
South Korea 13 4.4 12 5.4
UK 8 2.7 6 2.7
Netherlands 8 2.7 8 3.6
Poland 7 2.4 5 2.2
Multi-country 14 4.8 9 4.0
Other individual country 56 19.1 41 18.3
Study Type
Prospective 50 17.1 39 17.4
Retrospective 242 82.6 184 82.1
Unknown 1 0$3 1 0$4
Multicentre
Yes 180 61.4 135 60.3
No 112 38.2 88 39.3
Unknown 1 0$3 1 0$4
Registry
Yes 6 2$0 3 1.3
No 287 98$0 221 98.7
Study size (<50 patients)
Yes 103 35$2 88 39.3
No 190 64$8 136 60.7
Funding
Industry 79 27$0 63 28$1
Other (non-industry) 39 13$3 25 11$2
No 163 55$6 126 56$3
Unknown 12 4$1 10 4$5
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ded by the pharmaceutical industry (27%, n Z 79).
The overall median age for the pivotal RCT studies
was 61 years (IQR 56e62 years) compared to 64 years
(IQR 58e69 years) for the RWD studies. Twenty per
cent (n Z 60) of RWD studies included patients with a
median age >5 years older than the index trial. Where
reported, few studies included patients with an ECOG
performance status of 3, but the lack of a reported
performance status breakdown in most studies meant
comparison of the proportion of patients of ECOG
performance status 0e2 was not feasible. Less than 20%
of RWD studies reported comorbidity.
3.2. Study quality
All 293 studies were scored out of nine according to
the Newcastle Ottawa Scale (NOS). The distribution of
scores across the studies is presented in Fig. 1. Seventy-
eight per cent of studies (n Z 230) were classified as low
quality (score 0e3), 22% (n Z 63) moderate quality
(score 4e6), and no studies were classified as high
quality (score 7e9).
The proportion of studies meeting each individual
scoring criteria in the NOS is outlined in Table 2a for
case series (n Z 288) and Table 2b for cohort studies
(n Z 5). For the case series, we found that only 22% of
studies adequately evaluated survival (eg, method of
ascertaining patient deaths), and only 33% of studies
had sufficient follow-up to estimate survival. In addi-
tion, only 38% met the criteria for an adequate
description of the selection of participants.
Study quality was evaluated according to funding
status. For studies that were funded, there was a trend
towards better quality compared to those without
funding, although this was not statistically significant
(p Z 0.082). However, when studies with industry
(pharmaceutical) funding were compared to those
without, there was a statistically significant difference
with 35% (n Z 28) of studies classified as medium
quality, compared to 17% (n Z 34) of studies without
industry funding (p Z 0.001).
Supplementary Figs. 2e4 report quality trends ac-
cording to study country, tumour type, and individual
drug indication. The Netherlands had the highest pro-
portion of studies scoring 4e6 with 63% (n Z 5 out of
8), followed by multicentre international studies with
57% (n Z 8 out of 14), Italy with 36% (n Z 15 out of
42), and Spain with 33% (n Z 5 out of 15)
(Supplementary Fig. 2). According to tumour type,
sarcoma (46%, n Z 6 out of 13), gastric cancer (31%,
n Z 5 out of 16), and breast cancer (30%, n Z 7 out of
23) had the highest proportion of studies scoring 4e6
(Supplementary Fig. 3). When assessing quality ac-
cording to individual drug indications, almost half (44%,
n Z 20) had no RWD studies that scored 4e6
(Supplementary Fig. 4).
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Fig. 1. Histogram of the distribution of total scores for RWD studies appraised using the Newcastle Ottawa Scale.
Table 2a
Breakdown of scores for case series (n Z 288) using the modified
Newcastle Ottawa Score.
Validation Question Proportion meeting
criteria for YES score
1; Selection 108 (38%)
2; Exposure 188 (65%)
3; Outcome 64 (22%)
4; Confounding 173 (60%)
5; Follow-up 94 (33%)
6; Replication/inferences 102 (35%)
Table 2b
Breakdown of scores for cohort studies (n Z 5) using the Newcastle
Ottawa Score.
Validation Question Proportion meeting
criteria for YES score
1; Representativeness 0 (0%)
2; Selection of exposed cohort 3 (60%)
3; Exposure 1 (20%)
4; Outcome not present to start 5 (100%)
5a; Comparability 1 (20%)
6; Outcome 1 (20%)
7; Follow-up 1 (20%)
8; Adequacy of follow-up 3 (60%)
a Worth two points.
Fig. 2. Frequency chart reporting survival differences between
RWDa studies (n Z 224 for 37 drug indications) and their cor-
responding pivotal trial for that drug indication. aReal-world data
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The survival analysis included 224 of the initial 293
RWD studies identified (characteristics are described in
Table 1) for 37 of the 45 drug indications with RWD
studies.We summarised as a frequency chart the difference
in median overall survival reported for all 224 studies
compared to the index trial for each of the 37 drugsapproved indications (Fig. 2). Survival differences between
the RWD studies and their corresponding trial ranged
from 32 months to þ21 months, with an interquartile
range (IQR) (25th to 75th centile) from e 4$2 months to
þ1$6months. Thirty-sevenper cent (82/224) of studies had
superior survival outcomes compared to the pivotal trial,
compared to 63% (141/224) of studies that had inferior
survival outcomes. Across all RWD studies, the median
survival difference was statistically inferior to the pivotal
trial by 1$2 months (95% CI e1$7 to0$6, p < 0$001).
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tion of RWD studies that had survival outcomes that
were superior, inferior, or comparable with the pivotal
trial using 10% (better/worse) and 20% thresholds.
The median overall survival across all 224 RWD studies
was 13 months. At the 10% threshold, 26% of RWD
studies (n Z 58) had superior survival, 53% (n Z 119)
inferior survival, and 22% (n Z 49) comparable survival
to the pivotal trials. At the 20% threshold, 15% (n Z 35)
of RWD studies had superior survival, 40% (n Z 90)
inferior survival, and 45% (n Z 101) had comparable
survival.
When assessing the correlation between better sur-
vival and study quality, we found that lower quality
RWD studies were more likely to report superior sur-
vival outcomes compared to the pivotal RCT. At the
10% level, 30% of low-quality studies reported better
survival compared to 16% of moderate quality studies
(p Z 0.129). At the 20% level, 23% of low-quality
studies reported better survival, compared to 8% of
moderate quality studies (p Z 0.020).
We observed numerous examples of RWD studies for
the same indication that presented consistently superiorFig. 3. Range of differences in the median overall survival (OS) (mo
indications) for each drug indication relative to the median OS report(eg panitumumab for colorectal cancer) or inferior (eg
sorafenib for locally advanced thyroid cancer) median
overall results compared to the pivotal study (Fig. 3). In
addition, for some indications, we found contradictory
survival benefits reported (superior and inferior)
compared to the pivotal trial, with a wide range in the
survival outcomes reported (eg eribulin for 2nd to 5th
line metastatic breast cancer (RWD survival range 7$0
to þ14$8 months)).
This analysis was stratified according to study
quality. We found that compared to the pivotal trial,
moderate quality studies reported less variation in the
median OS (IQR 3.9 to 0.2) compared to low-quality
studies (IQR e 4.3 to 2.4). In addition, there was
markedly less variation in outcomes reported across
RWD studies of moderate quality for the same drug
indication compared to low-quality studies for the
same drug indication (Supplementary Figs. 5 and 6). A
similar trend was noted when comparing studies ac-
cording to funding status, with industry-funded studies
demonstrating less variation in survival outcomes
compared to those without industry funding
(Supplementary Figs. 7 and 8).nths) reported in individual RWD studies (n Z 224 for 37 drug
ed in the pivotal trial.
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This retrospective cohort study provides the first
systematic evaluation of RWD studies reporting the
effectiveness of cancer drugs for the treatment of solid
organ malignancies approved by the EMA and FDA
between 2010 and 2015. Overall, most EMA/FDA drugs
now have RWD studies available. However, their
methodologic quality is generally poor, with no high-
quality studies identified and approximately 80% of the
293 studies evaluated scoring 0e3 (out of 9) using the
Newcastle Ottawa Scale.
Patient selection, assessment and control of con-
founders, and evaluation of the study endpoint were
identified as the main limitations of these studies. These
studies would therefore not be considered of sufficient
methodological rigour to inform practice or policy, with
small, single-centre retrospective case series predominat-
ing. Only five of the 293 studies undertook a comparative
assessmentof the interventiondrugwitha comparator that
was the same as that evaluated in the pivotal trial.
The range of differences in median overall survival
outcomes in RWD studies compared to the corre-
sponding pivotal trial was large (over two years in some
examples) and conflicting, with some demonstrating
superior and others inferior outcomes for the same drug
indication. Importantly, the variation observed was
considerably more for low-quality studies compared to
those of high quality. Furthermore, low-quality studies
were more likely to report superior outcomes for the
intervention drug than the pivotal RCT.
Our findings are important as the narrative around
real-world evidence does not highlight the broad range
of studies of highly variable design and quality that
come under this umbrella term, including retrospective
case series data. While guidance on the design and
conduct of RWD studies are available, the reality is that
the term is used ubiquitously to cover all non-
randomised studies that use routine health re-
cords [12]. A major issue is that data from such studies
can be used as evidence of effect in routinely managed
populations without any explicit reference to their
methodological quality. For example, even for single-
arm observational studies e in particular those evalua-
tions within the context of compassionate access
schemes for drugs awaiting reimbursement e selection
bias remains a concern, as patients may receive a
particular intervention over and above a
comparator because physicians deem them to be fitter or
have a greater likelihood of tolerating treatment [11].
One immediate policy change that could be
implemented is for publishers to require that authors
routinely complete a methodological critical appraisal
checklist prior to submission to ensure transparency or
that peer reviewers are expected to complete this as part
of their assessment [16,17].From a wider structural perspective, the study high-
lights the importance of ensuring adequate funding is
available to develop high-quality outcomes research
programs to inform policy and practice. We found that
54% of RWD studies included in our evaluation did not
receive funding [18]. However, industry-funded studies
were more likely to be of better quality than other
studies. The actual cost of investing in RWD studies is
very small compared to drug development and the
amount spent on systemic therapies.
Even for well-designed observational studies, data may
be missing, incomplete or not coded according to an
established protocol. As such, extensive methodological
work is necessary to curate and develop specific indicators
(eg skeletal-relatedevents) toenablemeaningful evaluation
of interventions using routinely collected data [19,20].
Worryingly, in our analysis, we found that only a
very small proportion of studies used cancer registry
data (2%). A major advantage of registry data relative to
data from single or selected centres is the very large
sample size and coverage of eligible patients, especially
in single-payer systems.
However, the reality is that few countries have such
large-scale linked hospital registration systems in place.
This is due to the absence of a centralised data infra-
structure to collate these measures, heavily fragmented
public and private systems, and a lack of incentive
amongst physicians and providers [21]. In addition,
epidemiological research is still not a strategic priority
amongst both public and philanthropic funders who
have orientated almost exclusively around novel phar-
maceutical and basic cancer research [22].
The efficacy to effectiveness gap has been used to
describe differences in the outcomes observed in RCTs for
new interventions and their subsequent impact under
routine prescribing practice [23]. The efficacy to effective-
ness gap observed in our analysis is likely to be due to
differences in the characteristics of the population treated
or theway inwhich care is delivered in routinepractice [24].
With regards to the former, 40% of the RWD studies
included inour analysis had significantlyolderpopulations
compared to their corresponding pivotal trial, and some
studies included specific sub-populations, which are
frequently excluded from RCTs eg men and women with
brain metastases. However, data on performance status
and comorbidity was either not included or not presented
with sufficient granularity to enable direct comparison.
Our study findings of an efficacy to effectiveness gap
complement a recent study, which has focused on Medi-
care patients in the United States treated with FDA
approved cancer drugs between 2018 and 2020 [25], and a
further study assessing the correlation between hazard
ratios of observational studies undertaken using US pop-
ulation-based registries and their matched RCT across
different cancer interventions [26]. Of note, neither study
appraised the methods of the RWD studies as we have
done.
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study. We identified the corresponding pivotal trial
from a review of the regulatory documents at the time
of approval but acknowledge this is not always a one-
to-one match. We have used a single database
(PubMed) for identifying relevant articles up to August
2019, and it is possible that additional studies meeting
our inclusion and exclusion criteria may have been
missed. However, given the number and breadth of
drugs identified over a 10-year period (n Z 293) in this
evaluation e which uses an established search database
e we would not expect additional studies to signifi-
cantly change our findings with respect to quality and
outcomes. Similar methods have been used in other
studies that sought to compare outcomes reported in
observational studies with a defined cohort of pivotal
trials [29].
The study was limited in scope to an assessment of
those drugs reporting survival and did not include RWD
studies reporting QOL and alternative outcomes such as
progression-free survival if they did not also include
overall survival. The study was not designed to give a
precise estimate of effectiveness for each drug approved
indication but a broad overview of the variation in re-
sults as reported. Given the overall poor quality of
studies, the majority of which were case series, it is not
possible to undertake a formal meta-analysis of the
study results, and survival analyses reported are
exploratory in nature. The strengths of the analysis are
the inclusion of all relevant studies pertaining to
consecutive drugs approved over a six-year period. It
also provides an evaluation of study quality using an
established critical appraisal framework.
Our study is timely given that RWD studies are
increasingly being utilised to generate pharmacoeco-
nomic data [27], and gradually more countries are
looking to RWD studies to generate outcome-based
reimbursement data [28,29]. The trend for using RWD
has also extended to multiple Health Technology Au-
thorities such as the National Institute for Health and
Care Excellence (NICE) in England and Wales and the
Haute Autorite de Sante (HAS) in France [30].
Given the limitations of published RWD studies that
this study has identified, significant improvements in the
reporting of study methods and the design of studies are
necessary before RWD data is used to support changes in
clinical practice or reimbursement policy. Going forward,
we recommend researchers consider the methodological
frameworks developed by several organisations to sup-
port the design and conduct of RWD studies to improve
their quality and their ability to assess variation in access
to and outcomes of care [3,5,31,32]. In addition, we
recommend the routine inclusion of a critical appraisal
checklist as part of the submission process of RWD
studies, as the entrenchment of poor-quality research can
result in misinformation regarding the clinical effective-
ness of cancer drugs.5. Conclusion
Our study provides the first global systematic evaluation
of RWD studies assessing the effectiveness of FDA and
EMA approved drugs. We find that most new FDA and
EMA approved drugs for solid organ cancers have
RWD studies; however, the overall quality is very low
and would presently be of insufficient rigour to support
regulatory approvals and reimbursement. We also find
that the majority of RWD studies report survival out-
comes that are inferior to RCTs suggesting that the
benefits observed in trials are not translated into the real
world. Of concern is that low-quality studies are more
likely to overstate the benefits of new cancer drugs. The
standard of RWD studies of cancer drugs needs to
improve and be more consistent prior to its routine use
in support of clinical practice and policy change.Author contribution
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